Research programme: KRAS inhibitors - Boehringer Ingelheim/University of Texas M. D. Anderson Cancer Center
Latest Information Update: 28 Sep 2023
At a glance
- Originator Boehringer Ingelheim; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Cancer in Germany
- 28 Sep 2023 No recent reports of development identified for research development in Cancer in USA
- 12 Aug 2019 Boehringer Ingelheim and University of Texas M. D. Anderson Cancer Center agree to co-develop KRAS inhibitors for Cancer